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Summary 
CSPG4/NG2 is a multifunctional transmembrane protein with limited distribution in adult tissues 
including articular cartilage. The purpose of the current study was to investigate possible roles for 
CSPG4/NG2 in chondrosarcomas and to establish whether this molecule may have potential for 
targeted therapy. Stable knock down of CSPG4/NG2 in the JJ012 chondrosarcoma cell line by shRNA 
resulted in decreased cell proliferation and migration as well as a decrease in gene expression of the 
MMP (matrix metalloproteinase) 3 protease and ADAMTS-4 aggrecanase. Chondrosarcoma cells in 
which CSPG4/NG2 was knocked down were more sensitive to doxorubicin than wild type cells. The 
results indicate that CSPG4/NG2 has roles in regulating chondrosarcoma cell function in relation to 
growth, spread and resistance to chemotherapy and that anti-CSPG4/NG2 therapies may have 
potential in the treatment of surgically irresectable chondrosarcoma.  
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Introduction 
Chondrosarcoma is the most common primary malignant bone  tumour in adults over the age of 30, 
the incidence increasing with age. Prognosis depends largely on the histological grade. Low grade 
lesions are matrix rich with low cellularity. Higher grade tumours show increased cellularity, mitotic 
activity and cellular pleomorphism (Evans, et al., 1977). Conventional chondrosarcomas account for 
the vast majority and approximately 90% of these are low- to intermediate-grade tumours 
characterised by indolent clinical behaviour and low metastatic potential (Gelderblom, et al., 2008).  
Nevertheless the clinical management of chondrosarcoma remains a challenging problem. Disease 
free survival and overall survival of patients with chondrosarcoma have not shown any significant 
improvement over the last few decades. Whilst surgical resection remains the treatment of choice for 
the majority of chondrosarcomas and complete resection of low to intermediate-grade tumours is 
often curative, there are a significant number of chondrosarcomas, especially those arising in the 
pelvis or the spine that are difficult to remove with a wide surgical margin (Bergh, et al., 2001, Bruns, 
et al., 2001). In these instances local recurrence is almost inevitable and becomes a serious clinical 
problem.  
 
Although they may be used in treatment of metastatic or unresectable tumours, radiotherapy and 
chemotherapy are on the whole ineffective in the management of chondrosarcoma.  Recent advances 
in the understanding of the biology of chondrosarcomas have indicated potential targets for new 
therapies.  Somatic heterozygous missense mutations in the genes encoding isocitrate dehydrogenase 
(IDH)1  or IDH2 are frequent genetic events in low-grade and high-grade chondrosarcomas(Amary, et 
al., 2011) and compounds that specifically target mutant IDH1 R132H and IDH2 R140Q have been 
developed (Popovici-Muller, et al., 2012).  Therapies aimed at regulating activity of molecules and 
pathways involved in chondrosarcoma cell death/survival, proliferation or migration are also gaining 
interest (Dai, et al., 2011, Jamil, et al., 2010). Targeting specific molecules involved in chondrosarcoma 
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cell proliferation, migration and cell survival have the potential to improve outcomes in those patients 
with chondrosarcomas who have inoperable, recurrent and metastatic disease.  
One such candidate molecule is CSPG4/NG2. CSPG4/NG2 is a transmembrane protein expressed by 
cells typically as both a 250kD glycoprotein and a higher molecular weight, 400-450kD proteoglycan 
(Stallcup, 2002).  Initial reports suggested that in normal human adult tissues CSPG4/NG2 expression 
is restricted to a limited number of cell types including vascular pericytes, articular chondrocytes, 
microglia in the central nervous system and their neoplastic counterparts such as oligidendrogliomas, 
glioblastomas and chondrosarcomas. However it is now clear that CSPG4/NG2 is expressed in a 
broader range of tissues and tumours types such as childhood acute lymphoblastic leukemia, 
malignant melanoma, renal cell carcinomas, pancreatic cell carcinomas, triple-negative breast cancer 
and squamous cell carcinoma of the head and neck (Stallcup and Huang, 2008, Wang, et al., 2010). 
Importantly expression of CSPG4/NG2 is associated with tumour progression in high grade 
pleomorphic soft tissue sarcomas where metastases show greater than 80 fold increases in gene 
expression levels when compared to primary tumours (Benassi, et al., 2009, Cattaruzza, et al., 2013). 
The aim of the current study was to investigate possible roles for CSPG4/NG2 in chondrosarcomas and 
to establish whether this molecule may have potential for targeted therapy. 
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Methods 
Chondrocyte cell lines and tissues 
The JJ012 (grade II chondrosarcoma) cell line was kindly gifted by Professor Joel A. Block, Rush 
University Medical Centre, Chicago, USA.  Articular cartilage was donated by patients undergoing knee 
replacement surgery. Chondrosarcoma samples were obtained at the time of initial bone tumour 
biopsy or at definitive surgical resection. Ten chondrosarcoma samples were obtained from the 
archive of the Department of Pathology, Lothian University Hospital Trust. These were from 7 males 
and 3 females, age 21-77, and included 4 grade 2 chondrosarcomas from the pelvis, 2 grade 2 
chondrosarcomas from the scapula and calcaneus, a grade 3 chondrosarcoma from the proximal 
femur, a grade 2 pelvic chondrosarcoma metastatic to the lung, a grade laryngeal chondrosarcoma 
and a distal femoral clear cell chondrosarcoma. Patient samples were obtained with informed consent 
and ethical approval. 
CSPG4/NG2 gene knockdown in JJ012 cells was by shRNA (MISSION® shRNA Library , Sigma-Aldrich 
UK). In brief, five different constructs against CSPG4/NG2 were used together with GFP and non target 
controls. Cells were transfected by a serial 10 fold dilution of viral particles, following which they were 
cultured in medium containing puromycin. Resistant clones were expanded in medium containing 
puromycin and expression of CSPG4/NG2 assessed. Cells with maximum gene knock down (B3 cells), 
as assessed by RTPCR and western blotting, were used in subsequent experimental studies. 
Immunohistochemistry 
Sections were cut from formalin fixed, paraffin embedded blocks, dewaxed in xylene before being 
rehydrated in decreasing concentrations of alcohols. Antigen retrieval was achieved through 
incubation of samples in 10 mM sodium citrate solution at 95oC for 25 minutes. Sections were then 
treated in 3% H2O2 solution for 10 minutes. Blocking and antibody incubation steps were performed 
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in accordance with the Envision system (Dako, UK) instructions. Sections were immunostained stained 
using anti-CSPG4/NG2 rabbit polyclonal antibody ab86067 (Abcam, UK) at a concentration of 1:200. 
Diaminobenzidine solution was freshly prepared and added for nine minutes. Slides were countered 
stained in Haematoxylin and then dehydrated in increasing concentrations of alcohol before coverslips 
were mounted. 
Cell proliferation, adhesion and spreading assays 
Cell proliferation was assessed by using both the CyQUANT® Cell Proliferation Assay kit (Invitrogen, 
UK) according to the manufacturer’s instructions and the MTT assay (Peng, et al., 2012). Cell adhesion 
was assessed using methylene blue staining as described previously (Midwood and Salter, 1998).  In 
brief, 96 well plates were coated with 10µg/ml of type I, II or VI collagen, human fibronectin or bovine 
serum albumin (BSA) in 50µl PBS overnight at 4oC.  Cells were seeded at 2.0 x104/100µl in triplicate 
and allowed to adhere for 1hr at 37oC. After fixing in 4% formaldehyde, cells were stained in 1% 
methylene blue for 30min.  Adsorbed methylene blue was solubilized in 0.1N hydrochloric acid, mixed 
thoroughly, and the plate read at 630 nm on an ELISA reader (MR5000, Dynatech UK). Assessment of 
cell spreading was undertaken by allowing cells to adhere to 96 plate wells, coated with either collagen 
types  I, II, VI or fibronectin for 1hr at 37oC before fixing in 4% formaldehyde and imaging using a bright 
field microscope. Images were taken from at least three independent areas per well and the number 
of spreading cells as previously described(Humphries, 2000) were counted. 
Wound healing and inverted cell invasion assays 
A wound healing assay was used to assess cell migration in monolayer. Cells were seeded in 12 well 
plates at 7.5x104/well and grown until near confluent. A wound was made through the cells at the 
middle of the wells by scratching with a micropipette tip.  The wells were then washed carefully with 
media.  The area of wounding was imaged using bright field imaging immediately after and 10 hours 
after the scratch.  The percentage of area closed was assessed using T scratch software.   For the 
inverted cell invasion assay 100 µl of growth factor reduced Matrigel (BD Bioscience, UK) was pipetted  
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into each transwell of a 24 well plates and incubated for 30min at 37oC. When the Matrigel was set, 
100 µl of cell suspension (105 cells/ml) was pipetted onto the underside of the filter of the inverted 
transwells and incubated for 4 hours. After washing the transwells 3x with serum free medium, 100 
µl of either: serum containing media or serum containing media + Epidermal Growth Factor (EGF) was 
pipetted gently into the transwell on top of the matrigel. After 5 days the matrigel was stained with 
Calcein 4µM (Invitrogen, UK) and imaged by confocal microscopy. Optical sections were scanned at 
15µm intervals moving from the underside of the filter into the Matrigel and quantified using “Image 
J” software. 
Molecular studies and western blotting and flow cytometry  
RNA was extracted from cultured cells using an RNAse Mini kit (Qiagen, UK) following the 
manufacturer’s instructions and quantified using a Nanodrop1000 spectrophotometer (Thermo 
Scientific, UK). RT-PCR was carried out using Qiagen Long Range 2 step RT- PCR kit with a (G-Storm) 
thermal cycler. The qPCR reaction was carried out using SYBR Green and the Applied Biosystems 7500 
thermal cycler. RNA integrity testing and genomic DNA contamination steps were performed prior to 
RT-PCR and qPCR reactions. 
RIPA buffer with protease inhibitors was used to extract protein from cells for western blotting. In 
some studies protein extracts were incubated with chondroitinase ABC at 1U/ml for 45 minutes at 
room temperature.  Following western blotting, the membrane was incubated with 5% Marvel, 
washed with TBST and incubated with 1 µg/ml primary antibody, LHM2 (sc-53389, Santa Cruz 
Biotechnology USA) overnight at 4oC. The membrane was washed again and incubated with secondary 
antibody for 1hr at RT before further washes, incubation with ECL plus (Amersham, UK) and 
visualisation using a VersaDocTM imaging system (BIORAD, UK). Alpha tubulin was used as a positive 
control for protein loading. 
For flow cytometry 2x106cells were incubated with 50µl of FACS wash solution and mouse serum on 
ice for 15 minutes before incubation primary antibodies for 30 minutes at 4oC. Cells were then washed 
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and centrifuged for 5 minutes three times. Samples were mixed with 200µl FACS wash buffer and 
analysed using the FACS Calibur (BD, UK). For Annexin V staining, cells were resuspended in Hanks 
balanced salt buffer/Annexin V and incubated on ice for 10-15minutes before analysis using a 
FACscan system (BD, UK).   
Statistical analysis 
 The mean, standard deviation and standard error of the mean (SEM) were determined in each 
experiment. In each experiment, the samples were tested whether they are normally distributed or 
not.  Student unpaired t-test was used to identify statistically significant differences between two 
independent groups. For three independent groups, one-way ANOVA was used. The difference was 
considered statistically significant when p<0.05. 
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Results 
CSPG4/NG2 expression in the JJ012 chondrosarcoma cell line 
Gene expression of CSPG4/NG2 in the JJ012 cell line was similar to that of human articular 
chondrocytes and the transformed chondrocyte cell line C20 A4 as assessed by Q-PCR (results not 
shown). Western blotting showed that CSPG4/NG2 was expressed as a single, non-chondroitinase 
sulphated protein of approximately 270kD in the JJ012 cell line whereas articular chondrocytes 
expressed a predominantly chondroitinated proteoglycan of high molecular weight (Fig 1a).  
Immunofluoresence of CSPG4/NG2 distribution in JJ012 cells in monolayer culture showed 
predominantly cell membrane expression with focal enhancement as discrete projections (Fig 1b). In 
contrast articular chondrocytes showed both cell membrane and cytoplasmic expression in monolayer 
culture (Fig 1b).  All ten chondrosarcoma samples showed strong staining of the chondrosarcoma cells. 
The staining was most pronounced at the cell membrane but in all cases there was weaker, more 
diffuse cytoplasmic staining (Fig 1c). In cases where adjacent soft tissue was present only pericytic 
cells were seen to show positive staining 
Generation of a stable CSPG4/NG2 knockdown JJ012 cell line 
CSPG4/NG2 knockdown was carried out using the Mission TRC shRNA lentiviral transduction method. 
Five different constructs against CSPG4/NG2 (A, B, C, D and E) together with the negative (shRNA non-
target) and the positive (shRNA GFP) controls were used. The gene knockout efficiency was confirmed 
by QPCR and western blotting. QPCR showed that D1 and B3 constructs had the highest CSPG4/NG2 
gene knockdown efficiency among all colonies selected (Fig 2 upper panel). Western blotting 
confirmed decreased expression of CSPG4/NG2 in both B3 and D1 cells (Fig 2 lower panel). As protein 
expression in B3 cells appeared to be minimal this cell line was selected for use in subsequent studies.  
CSPG4/NG2 knock-down is associated with decreased cell proliferation 
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To assess the role of CSPG4/NG2 in chondrosarcoma cell proliferation, JJ012 (NG2+ve), B3 (NG2 -ve) 
cells and non-target cells were grown in culture for 24 and 48 hours and cell numbers assessed by two 
different cell proliferation assays.  With the CyQUANT® Cell Proliferation assay, B3 cell numbers were 
significantly lower in comparison to those of JJ012 cells following 48 hours in monolayer culture, whilst 
there was no difference in cell numbers between JJ012 cells and non-target (Fig 3a upper panel).  
Similar results were obtained with the MTT assay (not shown). To establish whether the increase in 
cell number following culture was a consequence of differences in cell proliferation and not cell death, 
annexin V expression, a marker of apoptosis, was assessed at 24 and 48 hours in culture. No significant 
difference in the percentage of annexin V positive cells in JJ012, B3 and non-target cell cultures was 
seen (Fig 3a lower panel) indicating that the difference in B3 and JJ012 cell numbers seen after 48 hour 
culture was most likely a consequence of differences in cell proliferation.  
Roles for CSPG4/NG2 in chondrosarcoma cell adhesion, spreading, migration and invasion. 
Both JJ012 (CSPG4/NG2 +ve) and B3 (CSPG4/NG2 -ve) cells adhered to collagen I, II, VI and fibronectin 
coated wells. There was no difference in adherence of JJ012 to the different matrix molecules whereas 
B3 cells appeared to show greater adherence to fibronectin in comparison to collagen (p=0.048) (Fig 
3b. upper panel). There was a trend for adherence of B3 cells to collagen II, VI and fibronectin coated 
wells to be greater than that of JJ012 cells although this did not reach statistical significance. There 
was no difference in the spreading of either JJ012 and control cells (non-target, CSPG4/NG2 +ve) cells 
on the different matrices. In contrast a statistically greater increase in spreading of B3 cells on collagen 
I, II, VI and FN (p<0.0001; p<0.008; p<0.0008 p<0.0003 respectively) was seen (Fig 3b lower panel).  In 
the wound healing assay, 10 hours following wounding in a monolayer culture, the closure of the 
wound area by B3 cells (54.6%) was significantly less (p=0.002) than that of both JJ012 cells (81.4%) 
and the non-target control cells (82.2%) (Fig 4a).  In contrast, there was no difference identified in the 
extent of invasion of the B3 and JJ012 cells into Matrigel in the inverted cell adhesion assay in the 
absence or presence of EGF as a chemoattractant (Fig 4b). 
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The effect of CSPG4/NG2 knockdown on cartilage matrix and protease expression  
As chondrosarcoma growth and spread requires both production of new cartilage-type matrix and the 
ability of the cells to migrate through the specialised matrix,  we assessed whether CSPG4/NG2 knock 
down influenced expression of cartilage matrix genes and proteolytic enzymes known to be involved 
in cartilage breakdown. There was no difference in expression of aggrecan or type II collagen, the 
major cartilage matrix molecules (not shown). In contrast CSPG4/NG2 knockdown had significant 
effects on protease gene expression (Fig 5a). Expression of both MMP3 and ADAMTS4 genes were 
decreased in B3 (CSPG4/NG2 –ve) cells in contrast to the CSPG4/NG2 +ve JJ012 and non-target 
transfected control cells. Conversely,  MMP13 gene expression was increased in the B3 cells. 
ADAMTS5 expression was minimal in all three cell types.  
CSPG4/NG2 expression is associated with relative resistance to doxorubicin but not docetaxel 
induced cell death. 
CSPG4/NG2 expression is associated with increased resistance to standard chemotherapy and 
radiotherapy in a number of tumour types. To investigate whether CSPG4/NG2 expression might 
contribute to chemoresistance in chondrosarcomas, viability and apoptosis of CSPG4/NG2 positive 
(JJ012) and negative (B3) chondrosarcoma cells was assessed following treatment with doxorubicin or 
doxotaxel. Initial studies identified an IC50 of 0.3μM and 10nm for doxorubicin and docetaxel 
respectively when applied to monolayer cultures of JJ012 for 48 hours (not shown) and these 
concentrations were used for subsequent studies. Assessment of annexin V expression by flow 
cytometry indicated that apoptosis was greater in B3 cells treated for 48 hours with 0.3μM 
doxorubicin in comparison to JJ012 cells and non-target control chondrosarcoma cells (Fig 5b). In 
contrast there was no significant difference in apoptosis between JJ012 and B3 cells after 48 hours 
treatment with 10nM docetaxel (not shown).  
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Discussion 
In this study, we have shown that knockdown of the multifunctional transmembrane proteoglycan 
CSPG4/NG2 in the JJ012 chondrosarcoma cell line is associated with a decrease in cell proliferation 
and migration, whilst cell spreading on extracellular matrices was increased. CSPG4/NG2 knock down 
was also associated with changes in expression of MMP3, MMP13 and ADAMTS4 although no 
significant differences were identified between the CSPG4/NG2 positive and negative cells in a 
transwell invasion assay. Importantly CSPG4/NG2 expression also appeared to provide a degree of 
protection against doxorubicin induced apoptosis. 
CSPG4/NG2 is recognised to be expressed by chondrocytes during cartilaginous bone formation, in 
articular cartilage and by chondrosarcomas (Fukushi, et al., 2003, Schwab, et al., 2009). The function 
of CSPG4/NG2 in cartilage has not been widely studied and is not entirely clear. In adult articular 
cartilage, CSPG4/NG2 appears to be important in the regulation of integrin dependent adhesion of 
chondrocytes to type VI collagen(Midwood and Salter, 2001),  but it is likely that this multifunctional 
proteoglycan will have a number of roles similar to that identified in other cell types and tissues in 
which it has been identified.  
Over the last decade or so, there has been significant advances in our knowledge of the structure and 
function of CSPG4/NG2. Structurally, CSPG4/NG2 consists of a large extracellular domain and a short 
76 amino acid cytoplasmic domain, separated by a 25 amino acid transmembrane domain (Nishiyama, 
et al., 1991). The extracellular domain includes sites for binding to a range extracellular matrix proteins 
(type V and type VI collagens), growth factors (FGF-2 and PDGFaa), integrins, matrix 
metalloproteinases (MMPs) and lectins.  Cleavage of CSPG4/NG2at membrane proximal sites of the 
extracellular domain results in the release of fragments that can stimulate endothelial cell migration 
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by interacting with galectin 3 and α3β1 integrin expressed by  endothelial cells (Fukushi, et al., 2004, 
Wen, et al., 2006). The intracellular domain mediates attachment to scaffolding proteins linking 
CSPG4/NG2 to intracellular signalling pathways and to the actin cytoskeleton(Chatterjee, et al., 2008) 
whilst phosphorylation of Thr2256 and Thr2314 within the intracellular domain has been found to be 
critical to balance between cell motility and cell proliferation (Makagiansar, et al., 2004, Makagiansar, 
et al., 2007, Wang, et al., 2010)    
As a consequence of its wide ranging activity in regulating cell function CSPG4/NG2has a number of 
predicted roles in tumourigenesis such as increased proliferation, migration, adhesion, invasion, 
metastasis and chemoresistance (Wang et al., 2010 Nicolosi, et al., 2015). In the current study, we 
have identified potential roles for this molecule in chondrosarcoma cell proliferation, migration and 
resistance to chemotherapy. CSPG4/NG2 functions predominantly as a co-receptor presenting growth 
factors to their cognate receptors and through interactions with extracellular matrix molecules such 
as collagens and fibronectin CSPG4/NG2 is linked to integrin-regulated signalling pathways. The 
decrease in proliferation and migration seen with CSPG4/NG2 knockdown  in the current study is likely 
to be a combination of disruption of this co-receptor activity. Previous studies, in other cell types, have 
shown that CSPG4/NG2 can bind to FGF-2 and PDGFaa and potentiate the mitogenic effect of the 
growth factors through presentation of ligands or by acting as a co-receptor (Grako, et al., 1999). 
Similarly, NG2-negative pericytes show significantly less proliferation than NG2-positive cells in 
response to FGF2 (Goretzki, et al., 1999). In association with integrins, CSPG4/NG2activates FAK and 
ERK signalling pathways potentiating proliferation (Yang, et al., 2004). CSPG4/NG2also plays a major 
role in migratory behaviour of cells. Targeting CSPG4/NG2reduces cell attachment and spreading 
(Bumol, et al., 1984) by interfering with integrin and non-integrin dependent cell adhesion to matrix 
components such as collagens II, V and VI, laminin and fibronectin. By regulating cellular attachment 
to these extracellular components CSPG4/NG2 can potentiate cell migration (Burg, et al., 1996, Tillet, 
et al., 1997). Indeed CSPG4/NG2 co-localisation with integrins and small GTPases in filopodia at the 
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leading edge of motile cells (Lin, et al., 1996a, Lin, et al., 1996b) may help to regulate the internal 
architecture of the cell in response to signals from its environment aiding migration. 
In addition to functioning as a co-receptor and transducing signals from the environment,  CSPG4/NG2 
has also been shown to actively modify the ECM through enhancing tissue breakdown. Studies from 
melanoma have demonstrated that mediates melanoma cell invasion through collagen I by activation 
of MT1-MMP and MMP2 (Iida, et al., 2007). Thus the observations that knockdown of CSPG4/NG2 in 
the chondrosarcoma cell line in the current study results in decreased expression of MMP3 and 
ADAMTS4 may be particularly relevant for chondrosarcoma cell invasion although, in the current 
study, we were unable to demonstrate a significant difference in cell invasion in a transwell assay. 
ADAMTS4 has a major role in cartilage breakdown in degenerative conditions such as osteoarthritis 
(Song, et al., 2007) whilst MMP3, in addition to having direct proteolytic effects on cartilage matrix 
molecules, activates other MMPs such as MMP-9(Vempati, et al., 2007) a type IV collagenase that has 
major roles in the invasion and metastasis of a range of cancer types (Stetler-Stevenson, 1990). In 
contrast to ADAMTS4 and MMP3, expression of MMP13 was increased with CSGP4/NG2 knock down. 
The reasons for this difference is not clear but a recent study has highlighted a relationship between 
NG2 and MMP13 and regulation of anoikis (Joo, et al., 2014) raising the possibility of a feedback loop 
between cell surface or extracellular CSPG4/NG2 levels and MMP13 production which has been lost 
in the B3 chondrosarcoma (NG2/CSPG4 knock down) cells .   
Knockdown of CSPG4/NG2 in our in vitro chondrosarcoma cell line increased the efficacy of 
doxorubicin inducing apoptotic cell death. Similar observations in which CSPG4/NG2 expression 
promotes chemoresistance have been made in other tumour types and appears to be mediated by 
CSPG4/NG2 association with integrin-induced activation of PI3K/Akt signalling, a critical component 
of cell survival signalling pathways(Chekenya, et al., 2008). CSPG4/NG2expression has also been linked 
to the up-regulation of drug transporter proteins in mixed-lineage leukemia (MLL) cells (Nicolosi, et 
al., 2015). A major problem with current management of chondrosarcoma treatment is resistance to 
15 
 
both standard chemotherapy and radiotherapy. Targeting CSPG4/NG2may have the potential to 
enhance chemotherapy effects in vivo. Significantly, as a cell surface molecule, CSPG4/NG2 is readily 
amenable to small molecule and antibody-based immunotherapy (Nicolosi, et al., 2015)  Early clinical 
trials with immunotherapy in melanoma and brain tumours have shown benefit with patients showing 
significantly increased survival and abolishment of metastasis (Mittelman, et al., 1995, Mittelman, et 
al., 1994, Mittelman, et al., 1992). The results of the current study indicate that CSPG4/NG2 has roles 
in regulating chondrosarcoma cell function in relation to growth, spread and resistance to 
chemotherapy and that anti-CSPG4/NG2 therapies may have potential in the treatment of surgically 
irresectable chondrosarcoma. 
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Figure Legends. 
Figure 1. CSPG4/NG2 expression in the JJ012 chondrosarcoma cell line. (a): Western blot of protein 
extracted from the JJ012 chondrosarcoma cell line (lanes 2 and 3) and chondrocytes retrieved from 
human knee joint osteoarthritic cartilage (lanes 4 and 5) which were untreated (lanes 3 and 5) or 
pretreated with chondroitinase ABC (lanes 2 and 4). Lane 1 contains molecular weight markers. (b) 
Immunofluorescent labelling of CSPG4/NG2 in JJ012 and osteoarthritic (OA) chondrocytes. Control = 
non-immune serum negative control. (c) CSPG4/NG2 expression in a human chondrosarcoma sample. 
Main figure bar = 500 µm, insert bar = 125 µm 
 
Figure 2. Knock-down of CSPG4/NG2 in the JJ012 cell line. Upper panel: relative RNA expression in the 
JJ012 cell line and in three clones (D1, D2 and B3) following shRNA lentiviral transduction. Lower panel: 
Western blot of extracted protein from the JJ012, D1, B3 and GFP transduced control.  
Figure 3. Effect of CSPG4/NG2 knock-down on (a) chondrosarcoma cell proliferation (upper panel) and 
apoptosis lower panel and (b) chondrosarcoma cell adhesion (upper panel) and spreading (lower 
panel). 
Figure 4. Effect of CSPG4/NG2 knock-down on (a) chondrosarcoma cell migration. Photomicrographs 
of  monolayer cultures immediately and 10 hours following wounding. The lower panel shows 
quantitative measurement of wound closure. (b) Chondrosarcoma cell invasion in a Matrigel transwell 
system using serum or EGF as chemoattractants. 
Figure 5. . Effect of CSPG4/NG2 knock-down on (a) cartilage MMP and aggrecanase expression. NT = 
non target control, B3 = CSPG4/NG2 knock down cells, JJ = JJ012 parent chondrosarcoma cell line. (b) 
Response to doxorubicin treatment. CSPG4/NG2 knock-down is associated with relative resistance to 
doxorubicin. Cells were treated with 0.3μM doxorubicin for 48 hours and the number of apoptotic 
cells counted. 
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